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Background. Gram-negative bacteria susceptible only to colistin (COS) are emerging causes of severe nosoco-
mial infections, reviving interest in the use of colistin. However, consensus on the most effective way to administer
colistin has not yet been reached.
Methods. All patients who had sepsis due to COS gram-negative bacteria or minimally susceptible gram-negative
bacteria and received intravenous colistimethate sodium (CMS) were prospectively enrolled. The CMS dosing sche-
dule was based on a loading dose of 9 MU and a 9-MU twice-daily fractioned maintenance dose, titrated on renal
function. For each CMS course, clinical cure, bacteriological clearance, daily serum creatinine clearance, and esti-
mated creatinine clearance were recorded.
Results. Twenty-eightinfectiousepisodesduetoAcinetobacterbaumannii (46.4%),Klebsiellapneumoniae(46.4%),
and Pseudomonas aeruginosa (7.2%) were analyzed. The main types of infection were bloodstream infection (64.3%)
and ventilator-associated pneumonia (35.7%). Clinical cure was observed in 23 cases (82.1%). Acute kidney injury
developed during 5 treatment courses (17.8%), did not require renal replacement therapy, and subsided within 10
days from CMS discontinuation. No correlation was found between variation in serum creatinine level (from base-
line to peak) and daily and cumulative doses of CMS, and between variation in serum creatinine level (from baseline
to peak) and duration of CMS treatment.
Conclusions. Our study shows that in severe infections due to COS gram-negative bacteria, the high-dose,
extended-interval CMS regimen has a high efﬁcacy, without signiﬁcant renal toxicity.
Severe nosocomial infections due to multidrug-resistant
(MDR) gram-negative bacteria account for high mor-
bidity and mortality [1]. The increasing incidence of
infections due to these strains and the lack of effective
antimicrobials in the drug-development pipeline [2]h a s
rekindled interest in the use of colistin as “last-line”
therapy [3]. However, in vitro efﬁcacy of colistin against
MDR Pseudomonas aeruginosa, Acinetobacter bauman-
nii, and Klebsiella pneumoniae (97%, 96%, and 88%,
respectively) [4] does not entail clinical cure, which, in
severe infections due to strains susceptible to colistin
only (COS), ranges from 15% to 75% [5–14]. Although
this wide range of in vivo efﬁcacy mainly depends on
substantial heterogeneity of illness severity, the role of
dosing regimen must be taken into account. The beneﬁt
of administering the right drug is often nulliﬁed by sub-
optimal drug exposure at the infection site due to
inadequate dosage. Despite >50 years of clinical use,
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reached [3]. Colistin exhibits a concentration-dependent
bactericidal activity, and its therapeutic efﬁcacy strictly depends
on the ratio of peak level to minimum inhibitory concentration
(MIC) or the ratio of area under the curve to MIC [15, 16]. In
critically ill patients, current colistin dosing regimens result both
in subtherapeutic peak concentration with respect to MDR
gram-negative bacteria MIC break points [17–20] and in pro-
longed time to steady state [19, 20], leading to suboptimal and
delayed effective treatment. Therefore, strategies involving
higher doses and longer dosing-intervals, along with loading
doses, have been proposed to obtain a more effective
killing [17–21]. However, clinical efﬁcacy and renal toxicity of
such regimens remain to be tested.
The purpose of this study was to test the renal toxicity along
withefﬁcacyofasalvagetherapywithahigh-doseandextended-
interval dosing regimen of colistin in a cohort of critically ill
patients with nosocomial infections due to COS gram-negative
bacteria.
METHODS
Study Population and Data Collection
A prospective, observational, cohort study was performed from
August 2010 to June 2011 in a 16-bed general intensive care
unit (ICU) at a teaching hospital. All critically ill patients who
had sepsis due to COS or minimally susceptible gram-negative
bacteria and were administered intravenous colistimethate
sodium (CMS) as a rescue therapy were enrolled. Patients
were excluded if they were <18 years old, pregnant, or breast-
feeding, or if they received colistin treatment for <72 hours.
Patients who, after a cured infectious episode, received a
second colistin course due to infection with another COS
gram-negative bacteria were considered as 2 different cases.
Patients were followed up until ICU discharge or death.
Primary outcomes were colistin nephrotoxicity and efﬁcacy.
A standardized case form was used to record patient charac-
teristics, including age, sex, weight, underlying comorbidities
(evaluated by Charlson comorbidity index), Acute Physiology
and Chronic Health Evaluation (APACHE) II score on admis-
sion, Sequential Organ Failure Assessment (SOFA) score on en-
rollment, type of infection, causative organism and in vitro
susceptibility, daily doses and duration of colistin therapy, cumu-
lative dose of colistin, coadministered antibiotics, nephrotoxic
agents (aminoglycosides, vancomycin, nonsteroidal anti-inﬂam-
matory drugs, intravenous radiocontrast agent, diuretics, manni-
tol), and clinical and microbiological responses to therapy.
Deﬁnitions and Microbiological Testing
Infections were deﬁned according to the Centers for Disease
Control and Prevention (CDC) [22]. Ventilator-
associated pneumonia (VAP) was deﬁned according to Ameri-
can Thoracic Society/Infectious Diseases Society of America
guidelines [23], and its bacteriological diagnosis required at
least 10
6 colony-forming units per milliliter in a quantitative
tracheal aspirate culture. Sepsis, severe sepsis, and septic shock
were deﬁned according to the American College of Chest
Physicians/Society of Critical Care Medicine consensus con-
ference criteria [24].
Follow-up specimens from tracheal aspirates, urine, blood,
and other suspected sites of infection were obtained twice
weekly and, when clinically indicated, from the start of CMS
therapy until discharge or death. Identiﬁcation of all
causative microorganisms was based on routine microbiologi-
cal methods. Antimicrobial susceptibility testing was per-
formed by MicroScan Walkaway System, using 42 GNC
panels (Siemens, New York, NY) and break points were those
deﬁned by the Clinical and Laboratory Standards Institute
[25]. Susceptibility to colistin was determined by the Etest
(BioMerieux, Marcy l’Etoile, France), using cation-adjusted
Mueller-Hinton agar, and the isolates were considered suscep-
tible if the MIC was ≤2 mg/L [25].
An isolate was deﬁned as COS if it was fully susceptible to
colistin but resistant to antipseudomonal penicillins, cephalos-
porins, carbapenems, monobactams, quinolones, and amino-
glycosides. MDR isolates fully susceptible to colistin and with
full or intermediate susceptibility to aminoglycosides were con-
sidered minimally susceptible to antibiotics [11].
Colistin Administration
Colistin was administered as CMS (Colomycin; Forest Labora-
tories, Bextley, United Kingdom) dissolved in 100-mL sterile
saline and was given over 30 minutes.
According to recent data [8, 15, 17–21], patients received a
loading CMS dose of 9 MU, followed by a maintenance dose
of 4.5 MU every 12 hours. In patients with moderate-to-severe
renal impairment (creatinine clearance rate, <50 mL/min),
dose and dosing intervals adjustments were made according to
Cockcroft and Gault creatinine clearance estimates: after a
loading dose of 9 MU, maintenance doses of 4.5 MU/24 hours
(for creatinine clearance rate in the 20–50 mL/min range) or
4.5 MU/48 hours (for creatinine clearance rate of <20 mL/min)
were administered.
Efﬁcacy and Nephrotoxicity Assessment
Efﬁcacy was evaluated by both clinical and bacteriological
responses to therapy. Clinical cure and failure were deﬁned as
resolution and persistence/worsening, respectively, of symp-
toms and signs of infection. Bacteriological clearance and
failure were deﬁned as eradication or persistence, respectively,
of COS gram-negative bacterial isolates on follow-up cultures,
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dent investigators evaluated type of infection and outcome.
Daily serum creatinine level and estimated creatinine clear-
ance rate were recorded from the ﬁrst day of CMS therapy
until discharge or death. Baseline glomerular ﬁltration rate
(GFR) was calculated by the abbreviated Modiﬁcation of Diet
in the Renal Disease equation [26]. In patients with normal
renal function (baseline serum creatinine level<1.2 mg/dL or
GFR ≥50 mL/min/1.73 m
2), nephrotoxicity was deﬁned as
doubling of baseline serum creatinine level or drop in baseline
creatinine clearance rate by ≥50%, while in patients with base-
line renal dysfunction (serum creatinine level ≥1.2 mg/dL or
GFR <50 mL/min/1.73 m
2), nephrotoxicity was deﬁned as an
increase by >50% of the baseline SCR level, a decrease by
≥20% from the serum creatinine clearance rate calculated at
baseline, or need of renal replacement therapy [7, 9]. Criteria
need to be fulﬁlled for at least 2 consecutive determinations 24
hours apart, after ≥2 days of CMS therapy. The Acute Kidney
Injury Network criteria [27] were used to evaluate the severity
of acute kidney injury (AKI).
Statistical Analysis
Serum creatinine level and creatinine clearance rate at baseline
(ie, start of CMS therapy), peak (ie, worst level reached during
treatment), the end of CMS therapy, and the end of follow-up
were considered for statistical analysis. Continuous normally dis-
tributed data are expressed as mean (±SD) and compared using
the unpaired Student t test. Nonnormally distributed data are ex-
pressed as median and interquartile range (IQR) and compared
using the Mann-Whitney U test. Categorical data are expressed
as number and percentage of events and compared using the
Fisher exact test. A Pearson regression analysis was performed to
clarify the association between variables. In all comparisons, a P
value <.05 was considered statistically signiﬁcant. Data were ana-
lyzed using SPSS, release 5.0.1 for Windows (Chicago, IL).
RESULTS
Characteristics of the Whole Sample
Out of 28 critically ill patients who were prescribed
colistin for COS gram-negative bacterial infections, 3 were ex-
cluded because CMS treatment duration was <72 hours
(because of discharge, for 2 patients, and death, for 1). Three
patients developed 2 infectious episodes due to different
species of COS pathogens, and each infection was included as
a separate case. Therefore, a total of 28 CMS treatments in 25
patients were analyzed.
Patients were predominantly males (75%), with a mean age
of 65±18 years. Main comorbid conditions were hypertension
(54.2%),ischemicheartdisease(45.8%),diabetesmellitus(25%),
chronic obstructive pulmonary disease (12.5%), and chronic
kidney disease (8.3%). Mean Charlson comorbidity index was
2.7 ±1.8. Mean APACHE II scorewas 18±6. Mean SOFA score
on day 1 of CMS therapy was 8 ±2. All patients underwent
mechanical ventilation. Median onset time of ﬁrst infectious
episode was 26 days (IQR, 18–48 days) from ICU admission.
In 16 of 28 infectious episodes (57.1%) clinical presentation
was severe sepsis, while in the other 12 (42.9%) it was septic
shock. Bloodstream infections (BSIs) occurred in 18 (64.3%)
cases, and VAP occurred in the remaining 10 (35.7%)
cases. Pathogens were A. baumannii in 13 (46.4%), K.
pneumoniae in 13 (46.4%), and P. aeruginosa in 2 (7.2%) epi-
sodes. All strains were fully susceptible to colistin, with MICs
of 0.19–1.5 mg/L, while 8 isolates of K. pneumoniae were sus-
ceptible also to gentamicin. Thus, 20 of the gram-negative
bacterial isolates were COS, while the remaining 8 were con-
sidered minimally susceptible strains.
In 14 episodes (50%) CMS was administered as monother-
apy, and in 14 (50%) it was employed as combination therapy
with aminoglycosides (69.2%) or carbapenems (30.8%).
In 22 episodes, patients with normal baseline renal function
(serum creatinine level, 0.7 ±0.2 mg/dL) received CMS at daily
and cumulative doses of 8.5 MU/day (IQR, 7.6–9 MU/day)
and 99 MU/course (IQR, 69–126 MU/course), respectively.
Median duration of treatment was 12 days (IQR, 10–17 days).
In 6 episodes, patients with abnormal baseline renal function
(serum creatinine level, 3.2 ±1.3 mg/dL) received a daily dose
of medication of 6.7 MU/day (IQR, 3.5–8 MU/day) and a
cumulative dose of 61 MU/course (IQR, 28–89 MU/course).
In this subset, the median duration of CMS administration
was 10.5 days (IQR, 8–18 days).
CMS Efﬁcacy
Clinical cure was obtained in 23 infectious episodes (82.1%).
Patients characteristics and clinical features of infectious episodes
with favorable and unfavorable therapeutic response are sum-
marized in Table 1. Bacteriological clearance was achieved in
73.9%(17)ofthecuredinfectiousepisodes,bythethirdday(IQR,
days 1–5) of CMS therapy in all BSIs, and by the eighth day
(IQR, days 3–10) in 4 (40%) VAP episodes. No recurrent infec-
tion by the same multiresistant pathogen was observed. Colistin
resistancewasneverobservedduringthefollow-upperiod.Break-
through superinfections by intrinsically colistin-resistant organ-
isms (Serratia marcescens and Proteus mirabilis) were observed
in 2 patients on days 12 and 14 of CMS treatment.
CMS Nephrotoxicity
No deterioration of renal function was observed during 23 CMS
treatment courses (82.1%). In this subset, the nonsigniﬁcant
increase of serum creatinine levels observed during treatment
(0.3 mg/dL [IQR, 0.12–0.57 mg/dL]) returned at baseline at
the end of the follow-up period (0.7 vs 0.7 mg/dL).
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different patients (one with preexisting renal dysfunction), with
an onset time of 7 days (IQR, 5.5–8.5 days). In these patients,
the serum creatinine level at the beginning of therapy was 0.95
mg/dL (IQR, 0.59–1.37 mg/dL) and peaked at 4.1 mg/dL
(IQR, 2.09–5.85 mg/dL; P=.036 vs. baseline) within a median
of 4 days (IQR, 2.5–5 days). At the end of CMS therapy the
serum creatinine level was 3.73 mg/dL (IQR, 0.64–5 mg/dL),
and during follow-up it dropped to 1.16 mg/dL (IQR, 0.55–
3.68 mg/dL; P=.53 vs baseline) within a median of 9.5 days
(IQR, 7–13 days) from CMS discontinuation. Temporal trends
of estimated creatinine clearance rates in patients with and
those without AKI are reported in Figure 1. All cases involved
nonoliguric episodes, and in no patients was renal replace-
ment therapy deemed necessary. One, two, and two patients
met the criteria for AKI stages I, II, and III, respectively. All
patients completed CMS therapy by dose reduction.
Mean age (63.7± 18 vs 72± 8 years), mean Charlson co-
morbidity index (2.2 ±1.6 vs 2.7± 1.8), and chronic kidney
disease (22% vs 20%) did not differ between patients with and
patients without AKI. Apart from AKI associated with use of
radiocontrast agents, no signiﬁcant predictor of renal impair-
ment was found in univariate analysis (Table 2).
Overall, no correlation was found between variation in serum
creatinine levels (percentage change from baseline to peak) and
daily (y =1×10
−6x +90.064; r=0.004; P= .98) (Figure 2) and
cumulative (y=0.0003x+6 0. 1 23 ; r=0. 06; P=.759) doses of
CMS, as well as between variation in serum creatinine levels
(percentage change from baseline to peak) and duration of CMS
treatment (y=−1.247x+107.9; r=−0.058; P=.7 7)(F ig ur e2).
DISCUSSION
The main ﬁnding of the present study is that, in critically ill
patients with life-threatening nosocomial infections due to
Figure 1. Estimated median creatinine clearance values on the ﬁrst day
of colistin treatment (baseline), at the lowest value reached (worst), on dis-
continuation of colistimethate sodium (CMS) treatment (stop CMS), and at
the end of follow-up (ﬁnal), in patients without (white box plots) and those
with (gray box plots) acute kidney injury (AKI). *P< .05 versus baseline.
Abbreviations: AKI, acute kidney ijury; CMS, colistimethate sodium.
Table 1. Patients’ Characteristics and Clinical Features of Infec-
tious Episodes Among 23 Infectious Episodes With and 5 Without







Age (years), mean ±SD 62± 18 76±3
Charlson comorbidity index,
mean ±SD
2 (1.5) 3.2 (2.2)
b
Surgical admission, No. (%) of
patients
8/20 (40) 4/5 (80)
APACHE II score, mean ±SD 18±6 25±7
b
SOFA score, mean ±SD 7.6± 2 9.1±2
ICU LOS (days) 56 (30–85) 75 (52–86)
ICU mortality, No. (%) of patients 5/20 (25) 5/5 (100)
b
Infectious episodes, No. (%) of
cases
23/28 (82.1) 5/28 (17.9)
Onset time of infection (days) 22 (12–47) 42 (23–54)
BSI, No. (%) of cases 13/23 (56.5) 5/5 (100)





No. (%) of cases
13/13 (100) 0/5
b
VAP, No. (%) of cases 10/23 (43.5) 0/5





No. (%) of cases
4/10 (40) 0/5 (0)
Clinical presentation, No. (%) of cases
Severe sepsis 16/23 (69.5) 0/5 (0)
b
Septic shock 7/23 (30.5) 5/5 (100)
b
Daily CMS dose (MU/d) 8.5 (7.3–9) 7.7 (5–8.5)
Cumulative CMS dose
(MU/course)
91 (61–122) 105 (17–142)
CMS monotherapy, No. (%) of
courses
12/23 (52.2) 2/5 (40)
CMS treatment duration (days) 11 (10–14.5) 15.5 (7–21)
Data are median value (interquartile range), unless otherwise indicated.
Abbreviations: APACHE, Acute Physiology and Chronic Health Evaluation;
BSI, bloodstream infection; CMS, colistimethate sodium; ICU, intensive care
unit; LOS, length of stay, MU, million units; SD, standard deviation; SOFA,
Sequential Organ Failure Assessment; VAP, ventilator-associated pneumonia.
a Three patients developed 2 infectious episodes due to different species of
pathogens susceptible only to colistin. Each infection was considered to be a
second case and was treated with CMS separately.
b P<.05 versus patients with response.
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extended-interval dosing regimen of colistin provides a high
degree of clinical cure, with no signiﬁcant renal toxicity.
Currently, COS A. baumannii, P. aeruginosa, and K. pneu-
moniae are emerging causes of severe nosocomial infections in
the ICU [28], and the daily total CMS dose is directly related
to clinical cure. Increasing the daily dose from 2 MU [7]t o9
MU [5] improves clinical cure rates from 51% [7] to 70% [5],
respectively. However, not only daily dose, but also fractioning
may affect efﬁcacy. A fractioned CMS regimen of 9 MU 3
times daily, currently prescribed in ICU practice, has been
associated with suboptimal and delayed steady-state concen-
trations [20, 21]. Therefore, a loading dose to rapidly achieve
target drug concentration and a dosing schedule that uses high
single doses at longer intervals has been proposed [17, 18,
20, 21]. On the basis of this pharmacokinetic/pharmacody-
namic background and severity of infection, we adopted a
CMS dosing schedule that involved a loading dose of 9 MU
and a maintenance dose of 4.5 MU every 12 hours [21]. This
regimen is consistent with data by Garonzik et al. [20], who,
on the basis of pharmacokinetic analysis of CMS and colistin
in critically ill patients, suggest that to obtain a colistin steady-
state plasma concentration of 2.5 mg/L, a 70-kg patient with a
creatinine clearance rate of 80 mL/minutes needs to receive a
CMS loading dose of 10 MU, followed by a maintenance CMS
daily dose of 10 MU.
Our dosing regimen resulted in a clinical cure rate of 82%,
which is above the best favorable response rates reported in
similar ICU settings with lower single doses and/or more frac-
tioned regimens [4–14]. Although the effectiveness of colistin
in pneumonia has been questioned because of its inadequate
lung diffusibility [9, 14], in our cohort clinical cure was
attained in 100% of VAP cases. The high single-
dose CMS dosing strategy may have contributed to this high
response rate, by increasing the colistin concentration in the
infected lung tissue. This hypothesis well ﬁts with results of
previous studies that reported a cure rate of only 57% in COS
P. aeruginosa VAP treated with a 2.2–4.3-MU
daily CMS regimen [9] and a cure rate of 75% in COS A. bau-
mannii VAP episodes treated with a 6-MU daily CMS regimen
[14]. Of note, however, bacteriological clearance in VAP
patients was only 40%. This low rate may reﬂect the well-
known persistent artiﬁcial and native airway colonization with
Enterobacteriaceae, A. baumannii, and P. aeruginosa, despite
therapeutic success, and may explain why clinical features and
quantitative cultures of bronchial aspirate are the most rel-
evant parameters in evaluating therapeutic response in
patients with VAP [29].
Since current reported rates of renal failure may reach 50%
[30, 31], colistin-related nephrotoxicity still remains a major
concern. Colistin induces tubular damage by increasing the
membrane permeability of epithelial cells, leading to leakage
of contents and cell death [32]. This effect has been related to
drug concentration and treatment duration [33,34], with a sig-
niﬁcant relationship between creatinine increase and cumulat-
ive dose of CMS [35]. In our study, de novo AKI was observed
only in 18% of CMS courses, a percentage similar to those
reported for lower single doses and more fractioned regimens
of CMS [7, 13, 35]. Consistent with previous reports adopting
the same AKI deﬁnition [7, 10, 22], in our sample AKI oc-
curred early, was not severe, did not cause discontinuation of
CMS, and subsided rapidly. In contrast to other reports [34–
36], in our study renal damage did not depend on daily CMS
doses, duration of treatment, or cumulative CMS doses. Titra-
tion of dose on the basis of renal function by prolonging
dosing interval, instead of by reducing the single dose (accord-
ing to colistin’s concentration-dependent pharmacodynamic
behavior), may have contributed to the low rate and moderate
severity of AKI [20]. This ﬁts well with a recent hypothesis
[37]thatattributesCMSnephrotoxicitytotheminimumplasma
concentration of colistin, as already demonstrated for amino-
glycosides[38]. However, because ofthe relativelysmall number
of patients, the study cannot provide an accurate estimate of
the relative contribution of colistin to renal dysfunction. Other
factors with a potentially crucial role in affecting kidney func-
tion include age, race, comorbidities, severity of critical illness,
hemodynamic status, and possible receipt of other coadminis-
tered nephrotoxic agents, such as radiocontrast medium. Never-
theless, even in presence of these favoring factors, the absolute
rate of AKI was low.
Some points of the study need to be underlined. Although
colistin monotherapy and extended-dose-interval regimens
may promote colistin resistance in presence of colistin-
Table 2. Potential Risk Factors for Acute Kidney Injury Associ-
ated With Colistimethate Sodium Therapy
Factor No AKI (n=23) AKI (n=5)
Septic shock 10 (43.5) 2 (40)
Concomitant nephrotoxic agents 20 (86.9) 4 (80)
Antibiotics 7 (30.4) 3 (60)
Diuretics 15 (65.2) 3 (60)
Radiocontrast agents 1 (4.3) 4 (80)
a
Mannitol 4 (17.4) 1 (20)
Daily CMS dose (MU/day) 8.3 (6.5–9) 7.1 (6–8.5)
CMS treatment duration (days) 11 (9.5–17.5) 12 (10–15)
Cumulative CMS dose 92 (56–126) 81 (64–92)
Data are No. (%) of infectious episodes or median (interquartile range).
Abbreviations: CMS, colistimethate sodium; MU, million units.
a P< .05 between groups.
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tin monotherapy was used in 50% of cases with no evidence
of resistance emergence during and after CMS therapy discon-
tinuation, as evaluated by surveillance cultures. Moreover, it is
difﬁcult to say whether combination treatment with carbape-
nems or other active drugs played a more important role than
giving a high dose of colistin. However, no differences were
found in clinical cure for combination therapy regimens as
compared to monotherapy, according to a recent comprehen-
sive review [39].
Our study has some limitations. Despite the prospective
design, the relatively small number of studied patients and the
absence of a control group represent major limitations. Data on
possible side effects of CMS apart from nephrotoxicity were
not evaluated actively. Finally, serum concentrations of
colistin were not measured, and therefore we cannot draw
any conclusion regarding peak levels reached with our dosing
regimen.
In conclusion, this study clearly shows that a 9-MU twice-
daily fractioned dosing regimen of colistin, along with a 9-MU
loading dose, can be used with satisfactoryefﬁcacyand relatively
low nephrotoxicity in life-threatening infections caused by
COS gram-negative bacteria, provided that an ongoing adap-
tion of dosing regimen to renal function is ensured. A multi-
center study, with proper study design and a relevant control
group, is needed to conﬁrm these preliminary data and to
better deﬁne the relationships between colistin blood levels ob-
tained by the high-dose, extended-interval dosing strategy
and renal toxicity.
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